Inventage Lab will be attending the American Diabetes Association (ADA) Scientific Sessions 2026, taking place June 5–8, 2026 in New Orleans, US.
The ADA Scientific Sessions is the world's largest conference on diabetes and metabolic disease, bringing together clinicians, researchers, and pharmaceutical and biotech professionals to discuss the latest advances in research and therapeutic innovation.
Inventage Lab is a publicly listed, clinical-stage biotech headquartered in South Korea, developing proprietary microfluidic-based drug delivery platforms. Our portfolio includes DrugFluidic®, a platform for long-acting injectable (LAI) formulations of small molecules and peptides; BioFluidic™, designed to optimize subcutaneous delivery of antibodies and protein therapeutics; and GeneFluidic®, an LNP-based delivery platform for nucleic acid therapeutics.
At ADA 2026, Inventage Lab will present research data on IVL3021 in poster format. IVL3021 is a long-acting injectable formulation of Semaglutide, a GLP-1 receptor agonist, developed on our DrugFluidic® platform, targeting a significant improvement in dosing convenience over the current weekly injection regimen.
We welcome inquiries from pharma and biotech companies interested in co-development and licensing partnership opportunities in the obesity and metabolic disease space.
